Published in Angew Chem Int Ed Engl on January 23, 2014
Protein degradation: Prime time for PROTACs. Nat Chem Biol (2015) 1.51
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol (2015) 1.46
SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov (2014) 1.25
Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol (2015) 1.21
The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Front Mol Neurosci (2014) 1.10
HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chem Biol (2015) 0.99
Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta (2014) 0.93
Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov (2016) 0.88
On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry. J Am Chem Soc (2016) 0.86
Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. Biochem J (2015) 0.85
Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. Angew Chem Int Ed Engl (2015) 0.82
A Small Molecule That Switches a Ubiquitin Ligase From a Processive to a Distributive Enzymatic Mechanism. J Am Chem Soc (2015) 0.82
UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration. Trends Mol Med (2015) 0.78
Covalent Tethering of Fragments For Covalent Probe Discovery. Medchemcomm (2016) 0.78
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. J Hematol Oncol (2016) 0.77
An Inducible System for Rapid Degradation of Specific Cellular Proteins Using Proteasome Adaptors. PLoS One (2016) 0.76
Small-molecule control of protein function through Staudinger reduction. Nat Chem (2016) 0.75
Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway. Biochem J (2017) 0.75
Degradation of Akt using protein-catalyzed capture agents. J Pept Sci (2016) 0.75
A Founder Mutation in VPS11 Causes an Autosomal Recessive Leukoencephalopathy Linked to Autophagic Defects. PLoS Genet (2016) 0.75
A Novel Destabilizing Domain Based on a Small-Molecule Dependent Fluorophore. ACS Chem Biol (2016) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol (2005) 14.42
Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science (1995) 12.94
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell (1994) 11.62
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc (2007) 9.92
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature (2007) 9.12
Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol (2009) 8.85
The ubiquitin system for protein degradation. Annu Rev Biochem (1992) 8.84
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell (2007) 8.48
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature (2009) 8.44
The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol (2004) 8.21
Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov (2004) 7.84
Identification of a primary target of thalidomide teratogenicity. Science (2010) 7.09
A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell (2006) 7.07
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A (1994) 6.74
HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem Biol (2008) 6.00
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A (1999) 5.28
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature (2010) 5.08
Proteasome inhibitors: from research tools to drug candidates. Chem Biol (2001) 5.06
Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl (2003) 4.50
Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med (2011) 4.09
Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01
MDM2 inhibitors for cancer therapy. Trends Mol Med (2006) 3.88
Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res (2007) 3.85
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood (2007) 3.67
Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett (1998) 3.32
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A (1996) 2.90
Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov (2010) 2.90
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A (1997) 2.81
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res (2008) 2.76
Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell (2010) 2.64
Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res (2007) 2.60
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure (2006) 2.56
Hydrolytic stability of hydrazones and oximes. Angew Chem Int Ed Engl (2008) 2.45
The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem (2001) 2.45
Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol (2008) 2.41
Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A (2009) 2.40
Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A (2001) 2.39
Chemical control of protein stability and function in living mice. Nat Med (2008) 2.37
An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell (2011) 2.35
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A (2009) 2.35
Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol (2012) 2.34
Will the ubiquitin system furnish as many drug targets as protein kinases? Cell (2010) 2.23
Conditional protein alleles using knockin mice and a chemical inducer of dimerization. Mol Cell (2003) 2.20
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J (2002) 2.17
Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc (2005) 2.12
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem (2004) 2.05
Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. Nat Chem Biol (2011) 1.98
Chemical genetic control of protein levels: selective in vivo targeted degradation. J Am Chem Soc (2004) 1.93
An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat Biotechnol (2010) 1.88
SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res (2008) 1.87
Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell (2000) 1.86
Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell (2012) 1.83
Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol (2012) 1.82
Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol (2011) 1.78
Conditional control of protein function. Chem Biol (2006) 1.78
Development of the proteasome inhibitor PS-341. Oncologist (2002) 1.76
Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry (1992) 1.74
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer (2004) 1.72
Catalytic mechanism and assembly of the proteasome. Chem Rev (2009) 1.72
Localization to the proteasome is sufficient for degradation. J Biol Chem (2004) 1.72
Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat Biotechnol (2010) 1.71
Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc (2007) 1.70
Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther (2009) 1.66
Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res (2009) 1.65
Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chem Biol (1999) 1.65
Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem Biol (2006) 1.65
Structure-based design of potent, conformationally constrained Smac mimetics. J Am Chem Soc (2004) 1.60
Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J Biol Chem (1996) 1.58
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem (2011) 1.58
Small-molecule displacement of a cryptic degron causes conditional protein degradation. Nat Chem Biol (2011) 1.57
Heat shock protein 90: inhibitors in clinical trials. J Med Chem (2010) 1.57
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett (1999) 1.54
Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem Biol (1998) 1.51
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem (2009) 1.50
A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol (2001) 1.49
Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem Biol (2008) 1.45
The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem (1997) 1.45
Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo) (1992) 1.44
Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket. J Med Chem (2000) 1.38
Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem (2008) 1.36
Small-molecule-mediated rescue of protein function by an inducible proteolytic shunt. Proc Natl Acad Sci U S A (2007) 1.35
Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J Am Chem Soc (2012) 1.34
Eponemycin analogues: syntheses and use as probes of angiogenesis. Bioorg Med Chem (1998) 1.34
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol (2011) 1.31
Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res (1999) 1.31
HaloTag7: a genetically engineered tag that enhances bacterial expression of soluble proteins and improves protein purification. Protein Expr Purif (2009) 1.27
Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol (2002) 1.27
Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteomics (2003) 1.27
Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. Chem Biol (2012) 1.26
A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol Biol (2003) 1.26
Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One. ACS Chem Biol (2008) 1.25
Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol (2001) 1.25
Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci (2008) 1.24
The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood (2010) 1.24
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat Genet (2011) 3.18
Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell (2007) 2.51
Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. Nat Chem Biol (2011) 1.98
Chemical genetic control of protein levels: selective in vivo targeted degradation. J Am Chem Soc (2004) 1.93
A chemical and genetic approach to the mode of action of fumagillin. Chem Biol (2006) 1.91
Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci U S A (2007) 1.75
Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem Biol (2008) 1.45
Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J Am Chem Soc (2012) 1.34
Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteomics (2003) 1.27
Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. Chem Biol (2012) 1.26
Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One. ACS Chem Biol (2008) 1.25
A role for planar cell polarity signaling in angiogenesis. Angiogenesis (2008) 1.18
Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol (2008) 1.18
Synthetic studies on amphidinolide B1. Org Lett (2006) 1.15
Identification of hydrophobic tags for the degradation of stabilized proteins. Chembiochem (2012) 1.11
Activation of the planar cell polarity formin DAAM1 leads to inhibition of endothelial cell proliferation, migration, and angiogenesis. Proc Natl Acad Sci U S A (2010) 1.10
Stereoselective assembly of a 1,3-diene via coupling between an allenic acetate and a (B)-alkylborane: synthetic studies on amphidinolide B1. Org Lett (2005) 1.09
Total synthesis and structure-activity investigation of the marine natural product neopeltolide. J Am Chem Soc (2009) 1.08
Chemical genetics: adding to the developmental biology toolbox. Dev Cell (2003) 1.08
Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. Angew Chem Int Ed Engl (2012) 1.07
Chemical inducers of targeted protein degradation. J Biol Chem (2010) 1.07
Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest. Proc Natl Acad Sci U S A (2006) 1.07
Triptolide-induced transcriptional arrest is associated with changes in nuclear substructure. Cancer Res (2008) 1.06
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorg Med Chem Lett (2008) 1.05
Studies on calcium dependence reveal multiple modes of action for triptolide. Chem Biol (2005) 1.01
Gene expression profile of the regeneration epithelium during axolotl limb regeneration. Dev Dyn (2011) 1.01
Highly efficient targeted mutagenesis in axolotl using Cas9 RNA-guided nuclease. Development (2014) 1.00
HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chem Biol (2015) 0.99
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. Nat Prod Rep (2013) 0.98
Triptolide directly inhibits dCTP pyrophosphatase. Chembiochem (2011) 0.95
Neurotrophic peptide aldehydes: solid phase synthesis of fellutamide B and a simplified analog. Bioorg Med Chem Lett (2006) 0.94
A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases. J Biol Chem (2003) 0.93
Total synthesis and biological evaluation of tyroscherin. Org Lett (2010) 0.92
Chemical approaches to controlling intracellular protein degradation. Chembiochem (2005) 0.91
Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs. Proc Natl Acad Sci U S A (2013) 0.91
Disruption of Wnt planar cell polarity signaling by aberrant accumulation of the MetAP-2 substrate Rab37. Chem Biol (2011) 0.89
Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD. Nephrol Dial Transplant (2010) 0.89
Total synthesis of TMC-95A and -B via a new reaction leading to Z-enamides. Some preliminary findings as to SAR. J Am Chem Soc (2004) 0.88
Development and characterization of proteasome inhibitors. Methods Enzymol (2005) 0.87
Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity. Chembiochem (2003) 0.86
Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors. J Med Chem (2008) 0.85
Characterization of a novel mammalian phosphatase having sequence similarity to Schizosaccharomyces pombe PHO2 and Saccharomyces cerevisiae PHO13. Biochemistry (2002) 0.84
Synthesis of the C3-C18 fragment of amphidinolides G and H. Org Lett (2007) 0.83
Microarray analysis of microRNA expression during axolotl limb regeneration. PLoS One (2012) 0.82
Targeting cyst initiation in ADPKD. J Am Soc Nephrol (2008) 0.82
Chemical biology: Greasy tags for protein removal. Nature (2012) 0.81
Developing microcolin A analogs as biological probes. Bioorg Med Chem Lett (2005) 0.81
Chemical genetics: a small molecule approach to neurobiology. Neuron (2002) 0.80
Identification and characterization of a peptidic ligand for Ras. Chembiochem (2010) 0.79
Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides. J Pharmacol Exp Ther (2010) 0.79
Myriaporone 3/4 structure--activity relationship studies define a pharmacophore targeting eukaryotic protein synthesis. Mol Biosyst (2006) 0.78
A HaloTag-based small molecule microarray screening methodology with increased sensitivity and multiplex capabilities. ACS Chem Biol (2012) 0.78
Generating and identifying axolotls with targeted mutations using Cas9 RNA-guided nuclease. Methods Mol Biol (2015) 0.78
HIV protease-mediated activation of sterically capped proteasome inhibitors and substrates. J Am Chem Soc (2011) 0.77
Natural product inhibitors of the ubiquitin-proteasome pathway. Curr Drug Targets (2011) 0.77
Cell Chemical Biology: Home of Exciting Chemical Biology. Cell Chem Biol (2016) 0.76
Unexpected stereochemical tolerance for the biological activity of tyroscherin. Bioorg Med Chem (2011) 0.75
Total synthesis of luminacin D. Org Lett (2002) 0.75
From Powerful Review Articles to Research Breakthroughs. Cell Chem Biol (2016) 0.75
Our Advisors, Our Ambassadors, Our Editorial Board Members. Cell Chem Biol (2016) 0.75
Inhibitors of NF-kappaB signaling: design and synthesis of a biotinylated isopanepoxydone affinity reagent. Bioorg Med Chem Lett (2002) 0.75
Voices of Chemical Biology: Charting the Next Decade. Cell Chem Biol (2016) 0.75
Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. J Med Chem (2017) 0.75